Cordero EI, Granell GM, Palanca SFJM

Language: Spanish
References: 26
Page: 37-40
PDF size: 60.13 Kb.

ABSTRACT

Background: The use of continuous infusions includes several disadvantages. Nevertheless, considering a pharmaco - kinetical point of view, «peaks and valleys» are avoided, which, when present, constitute a real disadvantage mainly on hemodynamics. The aim of the study was to analyze the clinical effect of 4 non depolarizing neuromuscular blockers (BNMND) used as continuous infusions. Material and Methods: A double blind prospective study was developed, including 60 healthy patients, randomly allocated in one of four groups (n=15), and all of them received a continuous infusion of a different BNMND (V, vecuronium; A, atracurium; M, mivacurium and Cisatracurium, C) using an initial dose of (3xDE 95) and a continuous infusion was instituted [V 0.8 micrograms. /kg / min, A 5.3 micrograms. /kg / min, C 1.2 micrograms. /kg / min]; clinical conditions for intubation as well as other relaxation parameters as: intubation time, maximum blockade index, clinical efficiency time (TEC), recovery index (IR 25-75%) and total length of blockade were measured using accelerometry. Statistical analysis was done using ANOVA, Scheffé and chi square tests (p ‹ 0.05). Results: Latency time of the blockade 90% was longer in group M (p ‹0.05) as compared with the other groups. The clinical conditions of intubation were excellent or good in 100% of the cases. Maximum blockade index (IBM) was significantly lower in group M as compared with the other groups, while the IBM of group C was significantly higher as compared with the rest of the groups (p‹ 0.05). The IR 25-75% was the more prolonged for C ( ‹0.01). The rest of variables did not show statistical differences. Discussion: The latency time of M was longer and it’s clinical length shorter; meanwhile IR 25-75% was more prolonged with C.

REFERENCES

1. Duracharme J, Donati F. Advances and use of muscle relaxant. Anesthesiol Clin North Am 1993; 2: 283-308.

2. Xue FS, An G, Liao X, Zou Q, Luo LK.The pharmacokinetics of vecuronium in male and female patients. Anesth Analg 1998; 86: 1322-1327.

3. Saavarese JJ. Review of new and currently used muscle relaxant In: ASA refresher course lecture. Washington DC, 1993. pp. 113.

4. Stevens JB, Walker SC, Fontenot JP. The clinical neuromuscular pharmacology of cisatracurium versus vecuronium during outpatient anesthesia. Anesth Analg 1997; 85: 1278-1283.

5. Crul JF. Muscle relaxants. Answer and to practical questions. Interfase. Belgica. 1992. pp. 210.

6. Savarese JJ. Some considerations on the new muscle relaxants. Anesth Analg 1998; Suppl: 119-127.

7. Scholz J, von-Knobelsdorff G, Peters K, Kycia B, Schulteam Esch J. Mivacurium: a new muscle relaxant compared with atracurium and vecuronium. Anaesthesiol Reanim 1997; 22: 95-99.

8. Ortiz JR, Carrascosa F. Mivacurio. Rev Esp Anestesiol Reanim 1997; 44: 315-320.

9. Bryson H M, Faulds D. Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Drugs 1997; 53: 848-866.

10. Tran TV, Fiset P, Varin F. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. Anesth Analg 1998; 87: 1158-1163.

11. Lienhart A, Deriaz H. Cisatracurium, applications cliniques. Ann Fr Anesth Reanim 1998; 17: 132-135.

12. Ortiz JR, Percaz JA, Carrascosa F. Cisatracurio. Rev Esp Anestesiol Reanim 1998; 45: 242-247.

13. Stevens JB, Walker SC, Fontenot JP. The clinical neuromuscular pharmacology of cisatracurium versus vecuronium during outpatient anesthesia. Anesth Analg 1997; 85: 1278-1283.

14. Silverman DG, Brill SJ. Monitoring neuromuscle block. Anesth Clin North Am 1994; 12: 237-260.

15. Helbo-Hansen H, Bang V, Nielsen H, Skovgaard LT. The accuracy of train of four monitoring at varyng stimulations currents. Anesthesiology 1992; 76: 199-203.

16. Fahey MR. Muscle relaxant and evaluation of intubation. Anesthesiology 1981; 55: 6-11.

17. Ali HH. Clinical Pharmacologic of mivacurium cloride infusion. Comparison with vecuronium and atracurium. Br J Anaesth 1988; 61: 541-546.

18. Rigg JD, Wilson AC, Pollard BJ. Mivacurium or vecuronium for muscular relaxation in day-case surgery. Eur J Anaesthesiol 1997; 14: 630-634.

19. Mirakhur RK, McCourt KC, Kumar N. Use of intermediate acting muscle relaxants by infusion: the future. Acta Anaesthesiol Belg 1997; 48: 29-34.

20. Mellinghoff H, Radbruch L, Diefenbach C, Buzello W. A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion. Anesth Analg 1996; 83: 1072-1075.

21. Ortiz J R, Percaz J A, Carrascosa F. Cisatracurio. Rev Esp Anestesiol Reanim 1998; 45: 242-247.

22. Xu QA, Zhang YP, Trissel LA, Gilbert DL, Martinez JF, Fox JL. Stability of cisatracurium besylate in vials, syringes, and infusion admixtures. Am J Health Syst Pharm 1998; 55: 1037-1041.

23. Lepage JY, Malinovsky JM, Malinge M, Lechevalier T, Dupuch C, Cozian A, et al. Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2OO 2-opioid anesthesia. Anesth Analg 1996; 83: 823-829.

24. Goudsouzian N, Chakravorti S, Denman W, Schwartz A, Yang H S, Cook D. Prolonged mivacurium infusion in young and elderly adults. Can J Anaesth 1997; 44: 955-962.

25. Booij LH. Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation. Pharm World Sci 1997; 19: 35-44.

26. Fisher DM, Wright PM. Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants? Anesthesiology 1997; 86: 567-575.